Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jul 9;182(1):7-9.
doi: 10.1016/j.cell.2020.06.017.

Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks

M Gordon Joyce  1 , Adam K Wheatley  2 , Kayvon Modjarrad  3
Affiliations
Comment

Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks

M Gordon Joyce et al. Cell. .

Abstract

The emergence of SARS-CoV-2 has driven a global research effort to identify medical countermeasures at an unprecedented pace. In this issue of Cell, Cao et al. identify thousands of SARS-CoV-2 neutralizing antibodies from convalescent donors. The authors improve our understanding of immunity against the coronavirus spike glycoprotein and detail novel pathways to rapidly identify and characterize protective monoclonal antibodies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Multifaceted Blueprint for Monoclonal Antibody Discovery and Development Rapid response to identify a protective monoclonal antibody is enabled by a combination of technological advances, matched with B cell selection criteria. High-throughput sequencing, B cell selection, and signature sequence panning identified thousands of SARS-CoV-2 reactive monoclonal antibodies, including a subset with ng/ul neutralization and protective capability, enabling rapid advancement to a phase I clinical trial.
See this image and copyright information in PMC

Comment on

References

    1. Cao Y., Su B., Guo X., Sun W., Deng Y., Bao L., Zhu Q., Zhang X., Zheng Y., Geng C. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell. 2020;182:1–12. - PMC - PubMed
    1. Chi X., Yan R., Zhang J., Zhang G., Zhang Y., Meng H., Zhang Z., Fan P., Dong Y., Yang Y. A Neutralizing Human Antibody Binds to the N-terminal Domain of the Spike Protein of SARS-CoV-2. Science. 2020:1–12. - PMC - PubMed
    1. Joyce M.G., Wheatley A.K., Thomas P.V., Chuang G.Y., Soto C., Bailer R.T., Druz A., Georgiev I.S., Gillespie R.A., Kanekiyo M., NISC Comparative Sequencing Program Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell. 2016;166:609–623. - PMC - PubMed
    1. Juno J.A., Tan H.-X., Lee W.S., Reynaldi A., Kelly H.G., Wragg K., Esterbauer R., Kent H.E., Batten C.J., Mordant F.L. Immunogenic profile of SARS-CoV-2 spike in individuals recovered from COVID-19. medRxiv. 2020 doi: 10.1101/2020.05.17.20104869. - DOI
    1. Kwakkenbos M.J., van Helden P.M., Beaumont T., Spits H. Stable long-term cultures of self-renewing B cells and their applications. Immunol. Rev. 2016;270:65–77. - PMC - PubMed

Publication types

Substances

LinkOut - more resources